BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON
Jul 17, 2026
Johnson & Johnson Tops Profit Expectations, Lifts Outlook Following Price… Read More
© 2026 CSRXP- All Rights Reserved
Updates
CSRxP: SENATE JUDICIARY COMMITTEE MUST REJECT BIG PHARMA’S FALSE RHETORIC ON INNOVATION, HOLD BRAND NAME MANUFACTURERS ACCOUNTABLE FOR PATENT ABUSE
Jul 13, 2026
Big Pharma’s Anti-Competitive Tactics That Extend Monopolies Are… Read More
DOSE OF REALITY: REPORT FINDS BIG PHARMA CONTINUES TO SET OUT-OF-CONTROL LAUNCH PRICES ON NEW MEDICINES COMING TO MARKET
Jul 2, 2026
Reuters Analysis Finds Average Launch Price For Drugs Approved By FDA in 2025… Read More
THEY SAID IT! LAWMAKERS HIGHLIGHT IMPORTANCE OF GREATER COMPETITION TO LOWER PRESCRIPTION DRUG PRICES AT U.S. SENATE HELP COMMITTEE MARKUP
Jun 18, 2026
Lawmakers Advance Bipartisan Solutions to Hold Big Pharma Accountable for… Read More
CSRxP COMMENDS U.S. SENATE HELP COMMITTEE FOR PASSING BIPARTISAN, MARKET-BASED SOLUTIONS TO HOLD BIG PHARMA ACCOUNTABLE, LOWER DRUG PRICES
Jun 17, 2026
Committee Markup Advances Solutions to Crack Down on Big Pharma’s Patent… Read More
SECOND OPINION: CLOSING LOOPHOLES BIG PHARMA EXPLOITS TO BLOCK COMPETITION AND KEEP DRUG PRICES HIGH WILL NOT UNDERMINE INNOVATION
Jun 16, 2026
Big Pharma’s Arguments Against Bipartisan, Market-Based Solutions to Foster… Read More
CSRxP ENCOURAGES HELP COMMITTEE TO ADVANCE BIPARTISAN, MARKET-BASED SOLUTIONS TO LOWER DRUG PRICES BY FOSTERING GREATER COMPETITION
Jun 16, 2026
Lawmakers Should Advance Biosimilar Red Tape Elimination Act, Medication… Read More
THEY SAID IT! LAWMAKERS AND EXPERTS SUPPORT BIPARTISAN, MARKET-BASED SOLUTIONS TO LOWER DRUG PRICES, FOSTER GREATER COMPETITION
Jun 5, 2026
U.S. House Judiciary Subcommittee Hearing Builds Bipartisan Momentum for ETHIC… Read More
CSRxP: U.S. SUPREME COURT DECISION HELPS SAFEGUARDS CRITICAL PATHWAY FOR GENERIC COMPETITION
Jun 4, 2026
Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. Ruling Will Help Protect… Read More
CSRxP ENCOURAGES HOUSE JUDICIARY IP SUBCOMMITTEE TO ADVANCE BIPARTISAN, MARKET-BASED SOLUTIONS TO LOWER DRUG PRICES BY FOSTERING COMPETITION
Jun 3, 2026
Lawmakers Should Advance the ETHIC Act and Skinny Labels, Big Savings Act to… Read More
THEY SAID IT! BROAD BASED SUPPORT FOR BIPARTISAN ETHIC ACT AND SKINNY LABELS, BIG SAVINGS ACT
Jun 2, 2026
Health Care Leaders and Policy Experts Agree Bipartisan, Market-Based… Read More
DOSE OF REALITY: AARP REPORT FINDS PRICES FOR TOP-SELLING BRAND NAME DRUGS RISE DRAMATICALLY IN THE U.S. WHILE FALLING IN OTHER COUNTRIES
Jun 2, 2026
Report Finds List Prices for Best-Selling Medicare Part D Prescription Drugs… Read More